Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study

2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy

(2020) Tristan Pascart et al.   JOINT BONE SPINE

Refractory gout – does it exist?

(2020) Werner Löffler et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

2020 American College of Rheumatology Guideline for the Management of Gout

(2020) John D. FitzGerald et al.   ARTHRITIS CARE & RESEARCH

Gout and hyperuricaemia in the USA: prevalence and trends

(2019) Gurkirpal Singh et al.   RHEUMATOLOGY

A Case Report of Immunosuppressant Medication-associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol-conjugated Uricase Enzyme Pegloticase

(2018) Brigid Freyne   TRANSPLANTATION PROCEEDINGS

Recapture and improved outcome of pegloticase response with methotrexate–A report of two cases and review of the literature

(2018) Sarah Y. Bessen et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout

(2017) Adey A. Berhanu et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

2016 updated EULAR evidence-based recommendations for the management of gout

(2016) P Richette et al.   ANNALS OF THE RHEUMATIC DISEASES

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy

(2015) Herbert S. B. Baraf et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

A Review of Uric Acid, Crystal Deposition Disease, and Gout

(2014) Fernando Perez-Ruiz et al.   ADVANCES IN THERAPY

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

(2014) Michael S Hershfield et al.   ARTHRITIS RESEARCH & THERAPY

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

(2014) Peter E Lipsky et al.   ARTHRITIS RESEARCH & THERAPY

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases

(2013) M. Jani et al.   RHEUMATOLOGY

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey

(2012) Puja P Khanna et al.   Health and Quality of Life Outcomes

Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008

(2011) Yanyan Zhu et al.   ARTHRITIS AND RHEUMATISM

Pegloticase and Chronic Gout--Reply

(2011) J. S. Sundy et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Refractory gout: what is it and what to do about it?

(2009) Edward Fels et al.   CURRENT OPINION IN RHEUMATOLOGY

Quality of Life and Disability in Patients with Treatment-Failure Gout

(2009) M. A. BECKER et al.   JOURNAL OF RHEUMATOLOGY